Newomics Inc. Places Its 100th Mass Spectrometry Front-end System
Customers include 8 of the top 10 global biopharmaceutical companies, and leading institutions in academia and biotech
Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research.